Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti‐catabolic drug denosumab
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
SUMMARY: Denosumab, a fully human monoclonal antibody, has been approved for the treatment of postmenopausal osteoporosis. The therapeutic effect of denosumab rests on its ability to inhibit osteoclast differentiation. Here, we present a computational approach on the basis of coupling a pharmacokinetics model of denosumab with a pharmacodynamics model for quantifying the effect of denosumab on bone remodeling. The pharmacodynamics model comprises an integrated systems biology‐continuum micromechanics approach, including a bone cell population model, considering the governing biochemical factors of bone remodeling (including the action of denosumab), and a multiscale micromechanics‐based bone mechanics model, for implementing the mechanobiology of bone remodeling in our model. Numerical studies of postmenopausal osteoporosis show that denosumab suppresses osteoclast differentiation, thus strongly curtailing bone resorption. Simulation results also suggest that denosumab may trigger a short‐term bone volume gain, which is, however, followed by constant or decreasing bone volume. This evolution is accompanied by a dramatic decrease of the bone turnover rate by more than one order of magnitude. The latter proposes dominant occurrence of secondary mineralization (which is not anymore impeded through cellular activity), leading to higher mineral concentration per bone volume. This explains the overall higher bone mineral density observed in denosumab‐related clinical studies. Copyright © 2013 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to Systems Biology: Design Principles of Biological Circuits
Alon, U. (2006) · doi:10.1201/9781420011432 · Cited by 2,825
Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.320 · Cited by 2,287
Functions of RANKL/RANK/OPG in bone modeling and remodeling
Boyce, B. F., & Xing, L. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.03.018 · Cited by 1,844 · cited 2×
“3, also considers the influence of the parathyroid hormone (PTH) and osteoprotegerin (OPG) on binding of RANK to RANKL [6], as well as the reduction of RANKL production because of increasing mechanical loading [41–44], see Equation (8) and [24, 32] for details.”
BackgroundAnthropometric Reference Data for Children and Adults: United States, 2003-2006: (623932009-001)
McDowell, M. A., Fryar, C. D., Ogden, C. L., & Flegal, K. M. (2008) · PsycEXTRA Dataset · doi:10.1037/e623932009-001 · Cited by 1,378
Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal Women
Bone, H. G., Hosking, D., Devogelaer, J.-P., Tucci, J. R., Emkey, R. D., Tonino, R. P., Rodriguez-Portales, J. A., Downs, R. W., Gupta, J., Santora, A. C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030897 · Cited by 1,347
Denosumab in postmenopausal women with low bone mineral density.
McClung, M. R., Lewiecki, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., Peacock, M., Miller, P. D., Lederman, S. N., Chesnut, C. H., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044459 · Cited by 1,228
Martin, R. B., Burr, D. B., Sharkey, N. A., & Fyhrie, D. P. (2015) · doi:10.1007/978-1-4939-3002-9 · Cited by 1,159
Osteocytes, mechanosensing and Wnt signaling
Bonewald, L. F., & Johnson, M. L. (2008) · Bone · doi:10.1016/j.bone.2007.12.224 · Cited by 1,076 · cited 1×
“In addition to their important role for the mineralization process (as discussed previously), osteocytes are known to act as key players for sensing changes of the mechanical loading and for transducing these changes into corresponding biochemical events, leading to increase or decrease of the bone matrix volume fract…”
BackgroundTransforming Growth Factor-β1 to the Bone
Janssens, K., ten Dijke, P., Janssens, S., & Van Hul, W. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0001 · Cited by 710
Learning versus confirming in clinical drug development*
Sheiner, L. B. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90160-0 · Cited by 633 · cited 1×
“Most of previous PK/PD-type models relate, on a simplistic phenomenological basis, drug exposure to related levels of so-called biomarkers, which serve as indicators for drug effectiveness and safety [17–19].”
BackgroundBody, J.-J., Facon, T., Coleman, R. E., Lipton, A., Geurs, F., Fan, M., Holloway, D., Peterson, M. C., & Bekker, P. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1933 · Cited by 490
Modeling the interactions between osteoblast and osteoclast activities in bone remodeling
Lemaire, V., Tobin, F. L., Greller, L. D., Cho, C. R., & Suva, L. J. (2004) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2004.03.023 · Cited by 452
Effects of cyclic hydraulic pressure on osteocytes
Liu, C., Zhao, Y., Cheung, W.-Y., Gandhi, R., Wang, L., & You, L. (2010) · Bone · doi:10.1016/j.bone.2010.02.006 · Cited by 88 · cited 1×
“3, also considers the influence of the parathyroid hormone (PTH) and osteoprotegerin (OPG) on binding of RANK to RANKL [6], as well as the reduction of RANKL production because of increasing mechanical loading [41–44], see Equation (8) and [24, 32] for details.”
Background
Cited by
A review of mathematical modeling of bone remodeling from a systems biology perspective
Cook, C. V., Lighty, A. M., Smith, B. J., & Ford Versypt, A. N. (2024) · Frontiers in Systems Biology · doi:10.3389/fsysb.2024.1368555 · Cited by 25
Hasegawa, C., & Duffull, S. B. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12324 · Cited by 18
“Other semimechanistic models have also been reported.(13,14) The former model comprises an integrated systems biology- continuum micromechanics approach (e.”
BackgroundJörg, D. J., Fuertinger, D. H., Cherif, A., Bushinsky, D. A., Mermelstein, A., Raimann, J. G., & Kotanko, P. (2022) · eLife · doi:10.7554/elife.76228 · Cited by 15
“Moreover, denosumab has been suggested to enable increased bone tissue mineralization, which leads not only to a halt of the BMD decline but also to a longterm increase in BMD (Scheiner et al., 2014).”
Background
Metadata
- Authors
- Scheiner, S., Pivonka, P., Smith, D. W., Dunstan, C. R., & Hellmich, C.
- Venue
- International Journal for Numerical Methods in Biomedical Engineering
- Publisher
- Wiley
- Published
- 2013-08-30
- Volume
- 30
- Issue
- 1
- Pages
- 1-27
- ISSN
- 2040-7939 (ISSN-L)
- 2040-7947
- OpenAlex
- W1919516818
- Cited by
- 52
- References
- 13
- FWCI
- 2.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.